<DOC>
	<DOCNO>NCT02182128</DOCNO>
	<brief_summary>Confirmation BIBF 1120 administer 150 mg twice daily ( b.i.d . ) 250 mg b.i.d . safe tolerable treatment Japanese patient advance solid tumour , overall safety , pharmacokinetic parameter , biomarkers , efficacy BIBF 1120 .</brief_summary>
	<brief_title>A Dose-escalation Study BIBF 1120 Japanese Patients With Advanced Solid Tumours</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>1 . Male female patient confirm diagnosis advance , non resectable and/or metastatic solid tumour ( except malignant lymphoma ) 2 . Patients respond conventional treatment , therapy proven efficacy available , amenable establish form treatment 3 . Patients recover therapyrelated toxicity previous chemo , hormone , immuno , radiotherapy ( except epilation ) least follow period time : four week chemotherapy ( least 2 week receive antimetabolite least 6 week nitrosourea mitomycin C ) two week receive hormone therapy four week receive radiation therapy ( 2 week radiation symptom control ) two week receive immunotherapy four week surgical procedure 4 . Age 20 year old 5 . Life expectancy least 3 month 6 . Eastern Cooperative Oncology Group ( ECOG ) performance score 0 2 7 . Patients retain significant physiological compensatory function without manifest mark disorder hematopoietic system , heart , lung , liver , kidney , etc. , i.e. , patient sufficient baseline organ function An absolute neutrophil count 1500/mm3 A platelet count 100000/mm3 A haemoglobin count 9.0 g/dL Serum creatinine le 1.5fold upper limit value normal range Bilirubin le 1.5fold upper limit value normal range Activities aspartate aminotransferase ( AST ) and/or alanine aminotransferase ( ALT ) less 1.5fold upper limit value normal range ( relate liver metastases less 2.5fold upper limit value normal range ) Saturation pulse oxygen ( SpO2 ) level le 90 % 8 . No participation clinical trial within 4 week start therapy within trial 9 . Written informed consent give consistent ICHGCP guideline Exclusion criterion 1 . Brain tumour , and/or brain metastasis require therapy 2 . History obvious pulmonary fibrosis interstitial pneumonitis chest Xray include pneumoconiosis radiationinduced pulmonary fibrosis expand radiation field 3 . Patients difficulty swallow study medication 4 . Gastrointestinal disorder might interfere absorption study drug ( Crohn 's disease , ulcerative colitis , broad resection stomach ) 5 . Patients diarrhoea great CTCAE grade 2 6 . Patients within 4 week major surgical procedure patient active ulcer injury incomplete wound heal 7 . History autoimmune disease 8 . History serious drug hypersensitivity 9 . History cardiac infarction congest heart failure New York Heart Association Classification ( NYHA ) II great within previous 6 month 10 . Serious illness concomitant nononcological disease difficult controled medication , active infectious disease , hepatic failure , renal failure , pulmonary fibrosis , interstitial pneumonitis , hemorrhagic tendency , heart disease ( congested heart failure , angina , arrhythmia , etc . ) , uncontrolled , severe hypertension , diabetes 11 . Pregnancy breastfeed 12 . Women men sexually active unwilling use medically acceptable method contraception 4 week last trial visit 13 . Patients positive test hepatitis B ( HBs ) antigen , hepatitis C ( HCV ) antibody , HIV antibody 14 . Alcohol drug abuse 15 . Patient suitable participation clinical trial opinion investigator</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>